BioinvestGPT ApS · Research use only
BioinvestGPT · BVCT web app · Introduction ·
Gain clinical foresight before every decision.
On , BioinvestGPT introduced the BVCT web app: R&D teams use predicted impacts on clinical effect sizes versus standard of care to de-risk decisions on targets, assets, trials, M&A and indication expansion, backed by a causal knowledge graph and virtual clinical trials. This page discusses no individual dashboard call.
In our view, most AI leaves you without clinical foresight until it’s too late. BVCT gives you clinical foresight before every decision.
- BioinvestGPT lets your R&D teams use reliably predicted impacts on clinical effect sizes — vs. SoC — to deterministically de-risk every decision across the asset lifecycle: targets, assets, trials, M&A, and indication expansion. bvct.bioinvestgpt.com →
- BioinvestGPT Knowledge Graph runs on 130,000+ causal entities and 8M+ causal edges, so you can visualize the causal rationale behind every GO / NO-GO — genes, pathways, and publications, all connected in 3D. User guide →
- BioinvestGPT Virtual Clinical Trials simulate the underlying causal biology of drug–body interactions, so you can de-risk first-in-class targets and enhance best-in-class assets where no precedent data exist — with a proven ex-ante accuracy of 95.6%, exactly where, in our view, every other platform falls short. See the ex-ante proof →
Side-by-side: how BioinvestGPT compares
| Pharma pain point | Many other AI platforms (in our view) | BioinvestGPT |
|---|---|---|
| Needs proprietary training data from pharma clients | YES | ZERO Works directly on drug designs — no client data required |
| Predicts clinical effect sizes and toxicity profiles | NO | YES HR / OR / RR for all registrational endpoints |
| Covers target → drug → trial → M&A → indication expansion | 1 | ALL 5 One unified platform |
| Passes large-scale ex-ante validation on ongoing human trials — before readout | NO (to our knowledge) | YES Head-to-head vs. SoC — 674 of 705 correct ex-ante calls |
| Works across all 14 drug modalities (our classification) | 1–2 | ALL 14 Small molecules through gene therapies |
Trying the web app at bvct.bioinvestgpt.com takes about a minute. Your feedback shapes the v1.
Alpha notice. When this introduction went out (), bvct.bioinvestgpt.com was an alpha release. It is provided for evaluation on an “as-is” basis without warranty as to specific outcomes or continuous availability.